{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Episode 497: Retatrutide Delivers Stunning Weight Loss Results In Triumph-1 Study","description":"In this episode of HeartDoc VIP, Dr. Joel Kahn breaks down the newly released \u2014 but not yet fully published \u2014 results from the highly anticipated Triumph-1 study on retatrutide, an investigational weight loss medication that\u2019s already generating major buzz in the cardiometabolic world. The reported weight loss results at 80 and 104 weeks are remarkable, with side effects appearing consistent with other medications in this class, including semaglutide and tirzepatide. Dr. Kahn discusses what\u2019s known so far, what questions still remain, and why the full peer-reviewed publication is so important before drawing final conclusions on risks and benefits. FDA approval may not be far away. Other topics in this packed episode include the troubling rise in fatal heart attacks among younger adults, a modified Mediterranean diet linked to lower diabetes risk, the connection between food preservatives and heart disease, atrial fibrillation in athletes, nitric oxide\u2019s role in brain health, fatty liver disease and cardiovascular risk, and how the American Heart Association\u2019s Life\u2019s Essential 8 score may predict diabetes risk in women. Thanks to Igennus for sponsoring this episode. Visit their site and use promo code DRKAHN to save on high-quality supplements. ","author_name":"Heart Doc VIP with Dr. Joel Kahn","author_url":"https:\/\/www.kahnlongevitycenter.com\/","html":"